Moran Wealth Management LLC Sells 121 Shares of argenx SE (NASDAQ:ARGX)

Moran Wealth Management LLC reduced its stake in argenx SE (NASDAQ:ARGX) by 1.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,438 shares of the company’s stock after selling 121 shares during the period. Moran Wealth Management LLC’s holdings in argenx were worth $2,509,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. KB Financial Partners LLC increased its stake in shares of argenx by 112.5% during the first quarter. KB Financial Partners LLC now owns 85 shares of the company’s stock valued at $27,000 after purchasing an additional 45 shares in the last quarter. Nkcfo LLC bought a new position in shares of argenx during the second quarter valued at approximately $37,000. Toronto Dominion Bank bought a new position in shares of argenx during the first quarter valued at approximately $36,000. Captrust Financial Advisors increased its stake in shares of argenx by 116.7% during the first quarter. Captrust Financial Advisors now owns 143 shares of the company’s stock valued at $45,000 after purchasing an additional 77 shares in the last quarter. Finally, Harbor Investment Advisory LLC bought a new position in shares of argenx during the second quarter valued at approximately $57,000. 52.77% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently weighed in on ARGX. Jefferies Financial Group raised their price target on shares of argenx from $605.00 to $628.00 in a research report on Monday, October 2nd. Wells Fargo & Company raised their target price on shares of argenx from $606.00 to $609.00 and gave the stock an “overweight” rating in a report on Friday, July 28th. HC Wainwright restated a “buy” rating and issued a $595.00 target price on shares of argenx in a report on Monday, September 18th. Morgan Stanley raised their target price on shares of argenx from $604.00 to $607.00 and gave the stock an “overweight” rating in a report on Wednesday, November 1st. Finally, Guggenheim raised their target price on shares of argenx from $545.00 to $590.00 and gave the stock a “buy” rating in a report on Friday, July 28th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $542.25.

argenx Stock Down 0.1 %

argenx stock opened at $489.31 on Tuesday. The company’s 50-day moving average price is $492.60 and its 200-day moving average price is $462.08. argenx SE has a twelve month low of $333.07 and a twelve month high of $550.76. The company has a market cap of $28.91 billion, a PE ratio of -117.62 and a beta of 0.79.

argenx (NASDAQ:ARGX) last released its quarterly earnings results on Tuesday, October 31st. The company reported ($1.25) EPS for the quarter, topping analysts’ consensus estimates of ($1.48) by $0.23. argenx had a negative net margin of 22.70% and a negative return on equity of 12.40%. The firm had revenue of $339.84 million during the quarter, compared to analysts’ expectations of $310.06 million. During the same period in the previous year, the company earned ($4.26) EPS. As a group, sell-side analysts expect that argenx SE will post -4.76 earnings per share for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC.